AZN

AstraZeneca PLC is a global biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines in oncology, cardiovascular, renal and metabolism, and respiratory disease areas. Founded through the 1999 merger of Astra AB and Zeneca Group, the company operates one of the world's leading pharmaceutical research and development organizations. AstraZeneca has built a strong pipeline through internal research and strategic partnerships, including the development of COVID-19 vaccines in collaboration with Oxford University. The company's key products include Tagrisso for lung cancer, Farxiga for heart failure and diabetes, and Symbicort for respiratory diseases. With headquarters in Cambridge, England, AstraZeneca maintains research centers and manufacturing facilities worldwide. The company has successfully rebuilt its pipeline following patent expirations in the 2010s, with oncology emerging as a major growth driver. AstraZeneca continues to invest heavily in research and development, particularly in precision medicine and biologics.